Enzon Pharmaceuticals (ENZN) 10-Q2013 Q1 Quarterly report

Filed: 10 May 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accumulated, acquire, acquiring, Additionally, adversely, advice, advisor, agreed, altogether, APA, assigned, ASU, auction, Audit, bankrupt, beginning, Belrose, cease, combination, committee, communicated, competent, component, comprehensive, conserving, consummate, contemplated, curve, cut, debit, Delaware, deleted, delisted, Delisting, depreciation, designed, disclosed, dissolution, diverse, documentation, documenting, Dollar, efficacy, ensure, entirety, entitled, entity, equipment, escrow, event, eventually, face, factor, fall, FASB, February, fluctuated, foregoing, free, gain, global, goal, guarantee, harmed, heavily, holder, iii, imminent, inability, input, insurance, intellectual, investor, issuer, iv, jurisdiction, Lazard, life, light, line, listing, LLC, location, lose, maintain, maximizing, monitor, NASDAQ, nonpublic, offer, ofour, ofthe, outsource, oversee, oversight, patent, percent, permitted, Plainfield, platform, processed, profitability, property, prospectively, public, Publicly, range, reallocate, reallocating, recent, recently, recommend, remediate, remediation, replaced, reserve, reserved, resolution, resolve, reversed, review, reviewing, SEC, secondary, significantly, South, summarized, Sylatron, technical, testing, title, Topic, unamortized, upcoming, vendor, wholly, wide, wind, workforce

Removed: Absent, accrue, adequate, amounting, Androgen, antagonist, approval, arrangement, assistance, assumed, bear, breast, Bridgewater, cancer, charge, chose, collaborator, colorectal, commercialize, compensated, consistent, contracted, coupon, curtail, custodial, deem, delay, derive, detail, dilution, discussed, drug, emerged, end, enhanced, enrolling, enrollment, environment, excluding, fail, flat, fund, funded, hand, human, identical, incremental, invested, irinotecan, leave, low, managed, messenger, metabolite, metastatic, minimal, mRNA, mutual, negotiated, NJ, note, Nox, obtain, open, organization, oriented, pediatric, PEGylated, personnel, Phase, pipeline, Piscataway, pose, preclinical, predominantly, privately, proceed, prostate, qualify, receipt, Receptor, recruit, regulatory, reinvesting, relocated, relocation, remaining, rent, represent, represented, repurchasing, resell, responsibility, retirement, ribonucleic, satisfy, selling, stage, strategic, Survivin, suspend, targeting, terminate, timeframe, transferred, trial, utilize, version

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ENZN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Enzon Pharmaceuticals, Inc. (the Company) on Form 10-Q for the quarterly period ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Timothy G. Daly, Vice President, Controller and Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 10, 2013	/s/ Timothy G. Daly
	Timothy G. Daly
	Vice President, Controller and
	Chief Accounting Officer
	(Principal Financial Officer)

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Enzon Pharmaceuticals, Inc. and will be furnished to the Securities Exchange Commission or its staff upon request.